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Introduction. From 20% to 40% of all patients commencing
dialysis are diabetic. The quality of glycemic control is an im-
portant determinant of outcome. The aims of this study were
to investigate the use of the continuous glucose monitoring
system (CGMS) to assess overall 24-hour glycemic control and
the effects of both nonglucose containing and more biocompat-
ible alternative peritoneal dialysis solutions in insulin-treated
continuous ambulatory peritoneal dialysis (CAPD) patients.
Methods. We studied 8 insulin treated diabetic CAPD pa-
tients. A CGMS probe was inserted [allowing automatic mea-
surement of interstitial fluid (ISF) glucose every 5 minutes, for
a 72-hour period]. The patients were then allowed home with
CGMS monitoring to assess the effect on glycemic control of
three differing peritoneal dialysis regimes. Phase 1 consisted
of three exchanges of 1.36% glucose and one of 3.86% glucose,
utilizing a lactate/bicarbonate buffer. Phase 2 was identical but
used lactate-buffered fluid alone. Phase 3 utilized a minimally
glycemic combination of one amino acid, one icodextrin, and
two 1.36% glucose lactate/bicarbonate-containing exchanges.
Results. ISF glucose measured by CGMS correlated well
with venous glucose measurements (r 2  0.82, P  0.0001).
There was a statistically significant difference in the mean ISF
glucose between all three phases (P  0.0001). The variation
in glycemic control was tighter during phase 3 [mean coefficient
of variation (CV) 0.21  0.03].
Conclusion. CGMS appears to be a clinically useful tool to
gain additional insights into the glycemic control of diabetic
CAPD patients. More biocompatible and nonglucose-con-
taining dialysis fluids seem to be associated with improvements
in glycemic control in this group of patients.
Diabetic nephropathy now accounts for 20% to 40%
of all patients entering end-stage renal failure (ESRF)
programs [1, 2]. The quality of glycemic control is known
to be an important determinant of the rate of progression
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of patients with diabetic nephropathy to increasing levels
of albuminuria (and by inference to ESRF) [3]. Further-
more, the predialysis glycemic control is also a determi-
nant of both mortality [4] and progression of diabetic
complications [5] for patients on continuous ambulatory
peritoneal dialysis (CAPD). Glucose exposure also ex-
poses tissue and plasma proteins to increased levels of
advanced glycation end products (AGEs) [6]. Accumula-
tion of AGEs in ESRF has been implicated in acceler-
ated atherosclerotic cardiovascular disease in this patient
group [7].
Diabetic CAPD patients are usually treated with dial-
ysis fluids utilizing glucose as the osmotic agent to pro-
vide ultrafiltration. This glucose is available to diffuse
from the peritoneal cavity into the patient’s circulation.
Despite this, insulin therapy is still usually optimized to
cope with hyperglycemia resulting from diet. Further-
more, the monitoring of glycemic control in this group
of patients is also suboptimal. Finger prick testing of
capillary glucose is limited in both the number of times
it can be undertaken in a day, and the fact that it is
impossible to monitor sleeping glycemic control with
this method. Conventional measures of overall glycemic
control such as serum fructosamine levels are prone to
artifactual effects brought about by chronic uremia and
dialysis treatment [8, 9]. Glycated hemoglobin appears
more reliable, but still reveals little information on 24-
hour glycemic profile.
The use of peritoneal dialysis solutions not using glu-
cose as their osmotic agent has been suggested as a strat-
egy to reduce glucose exposure in peritoneal dialysis
patients [10]. Both amino acids and icodextrin (glucose
polymer) are available as alternatives to glucose. The
effects of amino acid–based dialysis solutions in diabetic
peritoneal dialysis patients have been sparsely studied
[11]. The metabolic effects of icodextrin-based solutions
have been subjected to more extensive study (largely in
nondiabetic patients). Hyperglycemia and hyperinsulin-
emia are associated with the use of glucose (especially
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higher concentrations) in CAPD) and abrogated by the
use of icodextrin in both short- [12] and longer-term
studies [13]. There are no data available with respect to
diabetic CAPD patients. The effects of more biocompati-
ble peritoneal dialysis solutions, such as lactate/bicarbon-
ate-buffered glucose-based solutions, on glycemic con-
trol have not been studied.
Continuous glucose measurement of interstitial fluid
(ISF) is now possible. ISF glucose equilibrates with blood
glucose concentration and can be measured by automatic
sampling from a simply implanted subcutaneous sensor
[14]. This allows ISF glucose to be measured at 5-minute
intervals over a period of days. Subsequent downloading
of this data gives a continuous profile of glycemic control
over the study period. The continuous glucose monitor-
ing system (CGMS) has been validated as a reliable and
accurate measure of blood glucose in home use [15] in
nonuremic diabetic patients. The use of CGMS gives
potential insights both into overall glycemic control
(mean glucose) and variability of such control over the
full 24-hour period.
The aims of this study were to examine the effects of
biocompatible and minimally glycemic peritoneal dial-
ysis fluids on the quality of glycemic control in insulin-
treated diabetic CAPD patients.
METHODS
Patients
We studied eight patients with ESRF. All patients had
been treated with CAPD as their only dialysis modality.
No patient had received renal transplantation in the past.
Mean age was 52 years (range, 42 to 72 years). The mean
time the patients had been diabetic was 19 years (range,
12 to 29 years), the mean duration of ESRF treated with
dialysis was 58 months (range, 10 to 109 months). Five
patients suffered from type 2 diabetes mellitus and three
patients from type 1 diabetes mellitus. All were insulin
treated, without the addition of oral hypoglycemic agents.
Three patients were receiving twice daily premixed insu-
lin and the remaining patients were managed with multi-
ple boluses, four times a day, regimes including both
short- and long-acting insulin administered by the usual
subcutaneous route.
Study protocol
The study was approved by the Local Ethics Commit-
tee and informed consent was obtained from all enrolled
patients. All patients underwent standard peritoneal
equilibration testing with assessment of dialysis ade-
quacy (including assessment of residual real function).
Subsequent analysis was performed using the Adequest
2.0 program (Baxter, Waukegan, IL, USA).
The initial validation phase took place in a dedicated
clinical investigation unit. Intravenous canulas for sam-
pling of venous blood were inserted. Blood for the assess-
ment of standard biochemical and hematologic profiles
was taken, including hemoglobin A1c (HbA1c). The CGMS
probe (Medtronic MiniMed, Northridge, CA, USA) was
inserted subcutaneously and venous blood drawn every
15 minutes for measurement of glucose by a multichannel
analyzer and comparison with ISF glucose levels, for a
total of 6 hours. Glucose was measured by the glucose
oxidase reaction in both blood and in ISF by CGMS.
The probe was inserted into a differing position on the
anterior abdominal wall for each 72-hour segment of
study, avoiding any abnormal areas of skin, or scar tissue.
The CGMS functioned for 72 hours and automatically
measured ISF glucose levels every 5 minutes over the
complete study period. There was an additional calibra-
tion requirement to align the device with three capillary
glucose readings at the start of each 24-hour period.
The device itself is around the size of a pager and after
completion of the measurement period, all data were
downloaded to a personal computer for subsequent anal-
ysis. All patients continued their standard CAPD and
insulin regimes during this phase and received a meal.
The phase studying the effect of peritoneal dialysis
fluid composition on glycemic control took place with
the patients performing their own treatments at home.
Subjects attended the hospital to have the CGMS set
up. They then departed and underwent their standard
treatment within the community. Glucose monitoring
was augmented with four measurements of capillary glu-
cose during the study days. Each phase of the study
lasted for 72 hours. There was a 3-day washout period
on their standard CAPD regimen between each phase.
The CGMS was then returned, the data was retrieved,
and the equipment was set up for the next phase. No
changes to either routine diet or insulin therapy took
place over the entire study period. The CGMS was cali-
brated only to a maximum of 22.2 mmol/L, above that
patients were instructed to perform additional capillary
glucose measurements.
Five patients performed four 2 L exchanges per day,
two patients performed four 2.5 L exchanges, and one
patient performed three 2 L exchanges. No patient had
a dry period during the day. The patients were all estab-
lished on a regime of three 1.36% and one 3.86% glucose
bags per day. All patients within our peritoneal dialysis
program are dialyzed using lactate/bicarbonate-buffered
dialysis solutions (Physioneal, Baxter) as a routine. The
three phases of the study are summarized in Table 1.
Phase 1 was the default prescription. Phase 2 was identi-
cal but utilized conversion to lactate-buffered dialysis
solution alone (Dianeal, Baxter). Phase 3 was designed
as a minimally glycemic mixture of solutions. This in-
cluded one icodextrin bag (Extraneal, Baxter) to replace
the 3.86% glucose concentration bag in the previous two
investigatory phases. One of the 1.36% glucose bags was
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Table 1. Summary of peritoneal dialysis solutions used in each phase
of study
Phase 1 Physioneal 1.36%  3
Physioneal 3.86%  1
Phase 2 Dianeal 1.36%  3
Dianeal 3.86%  1
Phase 3 Physioneal 1.36%  2
Nutrineal  1
Extraneal  1
replaced with one containing 1.1% amino acids (Nutri-
neal, Baxter). The other two exchanges remained 1.36%
glucose Physioneal. Both of the nonglucose-containing
solutions are only licensed for single daily use. The one
patient receiving only three exchanges per day was
treated in identical fashion, but with one of the 1.36%
glucose bags not being utilized in each of the three phases
of study. The glycemic effect of these three phases was
assessed for each full 72-hour period using CGMS. The
order of the treatment phases were randomly allocated,
with only two of the patients undergoing the study in a
phase 1 to 3 order.
Statistical analysis
All data were analyzed using GraphPad Prism version
3.00 for Windows (GraphPad Software, San Diego, CA,
USA; www.graphpad.com). Correlation plots were sub-
sequently analyzed by linear regression. Coefficient of
determination was calculated from the Pearson correla-
tion. Further comparison of ISF and venous blood glu-
cose measurements was made using a Bland-Altman
plot. Intrapatient variability was assessed by calculation
of coefficient of variation (CV) coefficient. Data are ex-
pressed as mean  SEM (95% CIs) unless otherwise
stated. Box and whisker plots display the full range of
the data, the 25th to 75th centile (box) and the median.
RESULTS
Validation of CGMS
Accuracy of the CGMS measurement was demon-
strated by a high level of correlation of ISF glucose
with venous glucose levels (r 2 0.82, P  0.0001) (Fig. 1).
Values above 22.2 mmol/L were excluded. The quality
of the precision afforded by this technique, as compared
to laboratory-based measurement of venous glucose lev-
els is described in the Bland-Altman plot in Figure 2.
GGMS glucose measurement underestimated levels by
a mean of 17.1%  1.3% (19.7% to –14.5%).
Assessment of glycemic control using CGMS
The data from the CGMS recordings was broken down
into completed 9 a.m. to 9 a.m., 24-hour periods. Only
data from these fully comparable periods were included
Fig. 1. Correlation of interstitial fluid (ISF) glucose as measured by
continuous glucose monitoring system (CGMS) compared with venous
blood glucose levels, r 2  0.82, P  0.0001.
Fig. 2. Bland-Altman plot comparing interstitial fluid (ISF) glucose as
measured by continuous glucose monitoring system (CGMS) compared
with venous blood glucose levels.
in the further analysis to avoid bias from fragments of
days. Most patients therefore contributed three complete
traces for each of the three phases for further study. No
patient suffered any intercurrent illnesses during the study.
Mean HbA1c was 7.5% 0.4% (range, 6.4% to 9.5%).
The mean 24-hour CGMS glucose levels were 9.37 0.06
mmol/L (9.25 to 9.49 mmol/L) for phase 1, 10.05  0.07
mmol/L (9.9 to 10.2 mmol/L) for phase 2, and 7.82 
0.06 mmol/L (7.71 to 7.93 mmol/L) for phase 3. The
differences between phases 1 and 2, as well as the differ-
ences in mean 24-hour glycemic control between phases
1, 2, and 3 were all statistically significant to a P value
of 0.0001 (Fig. 3). This pattern of mean glucose, with
phase 2 being higher than phase 1 being higher than
phase 3, was repeated in all of the patients studied. The
stability of 24-hour glycemic control was assessed by
calculating the CV for each completed 24-hour period.
There was no difference in 24-hour CV between phase 1
and phase 2 (0.32  0.03) (0.24 to 0.39) and (0.34 
0.03) (0.26 to 0.41), respectively. CV in phase 3 (0.21 
0.03) (0.145 to 0.28) was appreciably lower than both
phase 1 and phase 2 (P  0.04 and 0.02), respectively
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Fig. 3. Mean 24-hour continuous glucose monitoring system (CGMS)
glucose level for each of the phases of study.
(Fig. 4). The CGMS 24-hour glucose profiles for all the
patients in each of the three study phases are summarized
in Figure 5. The improvement in the quality of glycemic
control associated with the use of nonglucose-based peri-
toneal dialysis fluids in a single representative patient is
summarized in Figure 6. The use of the phase 3 peritoneal
dialysis solutions was not associated with an excess of
either symptomatic or asymptomatic hypoglycemia. Only
one patient experienced CGMS readings above 22.2
mmol/L and these did not exceed 24 mmol/L by capillary
testing. As the data were only a very small part of the
total, they were included in the analysis at the maximum
value.
Dialysis adequacy and peritoneal function
All patients were adequately dialyzed, with reference
to urea clearance. Mean total body weight was 79.5 
4.4 kg (range, 69 to 104 kg). Mean weekly Kt/V was 2.18
0.05 (range, 2.0 to 2.36) and mean weekly creatinine
clearance (adjusted to 1.73 m2 body surface area) was
68.6  4.3 L/week (range, 58 to 86 L/week). Mean per-
centage contribution to total weekly Kt/V by residual
renal function was 23%  7.9% (range, 0% to 62%).
Three of the patients had less than 10% residual renal
function. Four of the patients exhibited a low average
peritoneal transporter status and the remaining patients
were high average.
DISCUSSION
Sustained hyperglycaemia over a full 24-hour period
is commonly experienced by diabetic CAPD patients,
despite acceptable measures of global diabetic control
(such as HbA1c). This study demonstrated that the qual-
Fig. 4. Coefficient of variability for 24-hour glucose level for each of
the phases of study.
ity of glycemic control can be influenced by the type of
peritoneal dialysis fluid used.
CGMS appears to be a clinically useful measure of
glycemic state, with both good accuracy and precision.
This is the first report of the use of this technology to
study glycemic control in uremic patients, or those on
dialysis. These data confirm the clinical utility seen with
the use of CGMS with nonuremic patients [15] is repli-
cated in this patient group. One of the disadvantages of
using icodextrin to treat diabetic patients is the interfer-
ence with glucose assays utilizing glucose dehydrogenase
enzymes of the pyrroloquinolineqinone class. This is
thought to be a result of the presence of maltose and
other oligosaccharide metabolites of icodextrin. The free
reducing group of the glucose molecule located at end of
the saccharide chain is capable of initiating the reaction
[16, 17]. This results in a highly variable degree of over-
estimation of blood glucose. ISF glucose is measured by
the glucose oxidase reaction and therefore not affected
by these issues.
The use of nonglucose-based peritoneal dialysis solu-
tions was associated with improved diabetic control. This
is the first report of this effect in clinical practice. Icodex-
trin has been reported to reduce hyperglycemia and hy-
perinsulinemia [12, 13]. There are no reports of the ef-
fects of amino acid–based solutions on glycemic control
in this patient group. The high carbohydrate load (150
to 300 g/day) that is associated with a substantial glucose
absorption from standard glucose–based peritoneal dial-
ysis solutions, can lead to long-term metabolic problems,
such as obesity and dyslipidemia [18]. The quality of
glycemic control as measured by CV of ISF glucose over
24 hours was also improved by the use of a minimally
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Fig. 5. The 24-hour completed continuous glu-
cose monitoring system (CGMS) glucose pro-
files for all patients in each phase of study,
phase 1 (A ), phase 2 (B ), and phase 3 (C ).
glycemic treatment regimen. It is not possible to extract
from these data any information of the relative contribu-
tions of icodextrin or the amino acid–based solutions on
the improved overall glycemic control, this would require
further study. The improvement of hyperglycemia is de-
sirable both for the development of further diabetic com-
plications and possible harmful effects of AGE forma-
tion as well as the undesirable effects of hyperglycemia
on ultrafiltration in diabetic peritoneal dialysis patients
[19]. It has been suggested that icodextrin is capable of
improving glycemic control and might improve ultrafil-
tration in diabetic patients on CAPD with poor glycemic
control [20]. We did not collect any data in this short-
term study on the influence of glycemic state on ultrafil-
tration volumes as this was beyond the scope of this
initial investigation.
The observed reduced hyperglycemia associated with
the use of lactate/bicarbonate-buffered dialysis fluid, as
compared to standard lactate-containing fluid, is intri-
guing. The absolute difference in mean 24 hours glucose
is relatively small, but is both statistically and clinically
significant. The very large amount of readings taken (about
4500 in each phase in this study) using CGMS allows resolu-
tion of these relatively small differences, although it re-
mains possible that small differences might be, at least
in part, due to increased treatment adherence in a study
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Fig. 6. The 24-hour completed continuous glu-
cose monitoring system (CGMS) glucose pro-
files for a single representative patient in each
phase of study, phase 1 (A ), phase 2 (B ), and
phase 3 (C ).
setting. The reasons for this difference can only be specu-
lated. However, possible explanations might include ef-
fects on absorption of carbohydrate load (influenced by
peritoneal pH), effects on metabolism, mediated for in-
stance by reduced absorption of lactate (systemic or por-
tal) or deleterious effects of glucose degradation prod-
ucts on intermediate metabolism. There are no reports
on glucose absorption being influenced by the use of
more physiologically formulated peritoneal dialysis solu-
tions [21]. It should be noted that the authors are not
aware of any data addressing this in diabetic patients.
The data in our study do suggest that lactate/bicarbon-
ate-buffered solutions do have an effect on glucose ab-
sorption and/or utilization (in diabetic patients receiving
insulin). The results of this study must be viewed with a
degree of caution due to the small number, heterogeneity
of the patients and short study period (too short to have
influenced glycated hemoglobin measurements). It is not
possible from these initial data to make robust recom-
mendations of the potential place for such monitoring
in ESRF patients.
CONCLUSION
CGMS appears to be a valid and clinically useful tech-
nology to gain additional insights into the glycemic con-
trol of diabetic CAPD patients, when compared to cur-
rently available methods. Reduction in the glucose load
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using icodextrin and amino acid containing peritoneal
dialysis solutions is associated with reduced hyperglyce-
mia and smoother glycemic control, without an excess
of hypoglycemia. The use of newer more physiologic
lactate/bicarbonate-buffered dialysis solutions seems to
also be associated with reduced blood glucose exposure.
The use of combinations of biocompatible and nonglu-
cose–containing dialysis solutions appear to offer an opti-
mized approach to the management of diabetic patients
treated with peritoneal dialysis. This approach warrants
further investigation.
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